ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

Cooperative Group chairmen Cool, But High Priority Trials To Continue

January 18, 1991

In Brief: Cancer Control Working New Review Guidelines: President Asks Congress For Cigarette Regulation

August 15, 1975

Burzynski, Monaco Clashed In Court

June 5, 1992

House-Senate Conferees agree On NCI Total for FY’89, Then Cut It $19 Million

August 26, 1988

FDA Approves Gleevec In 73 Days, A Speed Record.

May 18, 2001

Central Europe Faces Massive Public Education, Environmental Problems, Related To Cancer

August 23, 1991